[Ip-health] ​Bloomberg: CVS Will Exclude Xtandi From Formulary in 2017​

Ruth Lopert ruth.lopert at gmail.com
Thu Aug 4 12:47:33 PDT 2016


Shows that it's not only in 4th hurdle systems that rationing occurs.

On Tue, Aug 2, 2016 at 4:25 PM, Zack Struver <zack.struver at keionline.org>
wrote:

> http://keionline.org/node/2620
>
> ​Bloomberg: CVS Will Exclude Xtandi From Formulary in 2017​
>
> ​Submitted by Zack Struver on 2. August 2016 - 16:07​
>
> ​Bloomberg reported on August 2, 2016, that CVS Health announced that it
> plans to exclude 35 drugs from its formulary
> <
> http://www.bloomberg.com/news/articles/2016-08-02/cvs-plans-to-bar-novartis-cancer-drug-from-2017-covered-drugs
> >
>  beginning in 2017, including Xtandi, bringing the total number of excluded
> drugs to 131.
>
> CVS will continue to reimburse Zytiga (abiraterone), a drug for prostate
> cancer that is marketed by Janssen. AS KEI noted, one study found that
> Xtandi
> would be more cost-effective than Zytiga <http://keionline.org/node/2473>
> if
> the price was decreased by at least 26%.
>
> CVS operates various prescription drug services, including Caremark, one of
> the largest U.S. pharmacy benefit managers, as well as the largest Medicare
> Part D insurer, SilverScript <https://www.silverscript.com/about-us.aspx>,
> which covers over 5 million Medicare patients. CVS reported that its
> pharmacy services businesses earned $28.8 billion in net revenue
> <
> http://hsprod.investis.com/shared/v2/irwizard/sec_item_new.jsp?epic=cvs_caremark&ipage=10911067&DSEQ=&SEQ=&SQDESC=
> >
> in
> the first quarter of 2016
> This exclusion marks the first time that CVS has removed a brand-name
> cancer medicine from its formulary. According to a press release
> <
> http://investors.cvshealth.com/~/media/Files/C/CVS-IR-v3/documents/02-aug-2016/2017-standard-formulary-list-of-removals-and-updates.pdf
> >,
> CVS plans to remove the 35 drugs from its formulary to “help reduce costs
> for clients and plan members.” CVS also explained that 10 of the drugs to
> have their coverage revoked are “hyperinflationary drugs,” defined as
> “products with egregious cost inflation that have readily-available,
> clinically-appropriate and more cost-effective alternatives.”​
>
> --
> Zack Struver, Communications and Research Associate
> Knowledge Ecology International
> zack.struver at keionline.org
> Twitter: @zstruver <https://twitter.com/zstruver>
> Office: +1 (202) 332-2670 Cell: +1 (914) 582-1428
> keionline.org
> _______________________________________________
> Ip-health mailing list
> Ip-health at lists.keionline.org
> http://lists.keionline.org/mailman/listinfo/ip-health_lists.keionline.org
>



More information about the Ip-health mailing list